Patent Covers Generation of Multiple Audience-Adaptive Commentary Video Variants While Preserving Factual IntegrityFREEHOLD, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer products and generative AI publishing and software, today announced that its subsidiary, Avalon Quantum AI LLC, has filed a new U.S. provisional patent application covering an artificial intelligenc ...

Core Insights - The company has successfully converted the majority of its outstanding debentures, significantly strengthening its balance sheet and enhancing shareholder value [1][3][4] Financial Overview - The debentures originated from a June 2024 financing round with an aggregate principal amount of $2.8 million, of which $288 thousand was repaid in cash and $2.6 million was converted into common stock [2] - The conversion eliminates the majority of Avalon's outstanding debt, improving financial transparency and supporting long-term shareholder value creation [2][3] Strategic Implications - The conversion is viewed as a meaningful milestone that strengthens the company's capital structure, enhances capital efficiency, and improves overall financial flexibility [4] - This progress aligns with the company's recent return to compliance with Nasdaq's minimum stockholders' equity requirement, positioning it to execute strategic growth initiatives with greater confidence [4] Company Profile - Avalon GloboCare Corp. focuses on developing precision diagnostic consumer products and advancing intellectual property in generative AI publishing and software [5] - The company is currently marketing the KetoAir™ breathalyzer device, which is registered as a Class I medical device with the U.S. FDA, and plans to develop additional diagnostic uses for this technology [5]

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.Here's the latest list of major oversold players ...

Core Insights - The real estate sector has several oversold stocks that present potential buying opportunities for undervalued companies [1] Group 1: Oversold Stocks - Douglas Emmett Inc (NYSE:DEI) has an RSI of 28.5, with a recent stock price of $10.55, down 2.3% on Monday, and a 52-week low of $10.52 [6] - Hudson Pacific Properties Inc (NYSE:HPP) has an RSI of 28.2, with a recent stock price of $9.03, down 3.9% on Monday, and a 52-week low of $9.00 [6] - Avalon Globocare Corp (NASDAQ:ALBT) has an RSI of 27.8, with a recent stock price of $0.81, down 0.9% on Monday, and a 52-week low of $0.78 [6]

Provisional Patent Application Covers Systems and Methods for Evidence-Constrained, Audience-Adaptive Generation of Automated Commentary VideosFREEHOLD, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer products and generative AI publishing and software, today announced that its subsidiary, Avalon Quantum AI LLC, has filed a U.S. provisional patent application covering a ...

Core Viewpoint - Avalon GloboCare Corp's stock is experiencing a decline without any specific news to justify the movement, despite the recent FDA registration renewal for its KetoAir device [1] Group 1: Product Overview - The KetoAir device is a handheld breathalyzer that measures breath acetone concentration (BrAce), a biomarker linked to fat metabolism and nutritional ketosis [2] - Utilizing nano-sensor technology, KetoAir offers real-time, non-invasive insights into metabolic states through breath analysis, targeting individuals on ketogenic diets for various purposes [2] - The device is compatible with both iOS and Android smartphones, with applications available on major app stores [3] Group 2: Market Strategy - Avalon GloboCare plans to launch the KetoAir device in both B2B and B2C markets, enhancing marketing and distribution through its subsidiary, Avalon Quantum AI, LLC [3] - Marketing efforts for the device are set to begin in the second quarter of 2026, which is viewed as a significant milestone for the company [4] Group 3: Stock Performance - The stock is currently trading 31.1% below its 20-day simple moving average (SMA) and 55.5% below its 100-day SMA, indicating strong bearish momentum [5] - Over the past year, shares have decreased by 70.51%, and the stock is closer to its 52-week lows than highs [5] - As of the latest publication, shares were down 23.64% at $0.84, marking a new 52-week low [7]

Core Insights - Avalon GloboCare Corp. has renewed the U.S. FDA establishment registration for the KetoAir™ device, a handheld breathalyzer for ketogenic health management [1][5] - The KetoAir™ device measures breath acetone concentration, providing real-time insights into metabolic state for individuals on ketogenic diets [2][5] - Avalon plans to launch KetoAir™ in both B2B and B2C markets using its Catch-Up™ platform, which is powered by generative AI for marketing and distribution [3][4] Company Overview - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and advancing intellectual property in cellular therapy and generative AI [5] - The KetoAir™ device is registered as a Class I medical device with the FDA and is intended for weight management, athletic performance, and lifestyle-based ketogenic programs [2][5] - The company is also advancing its intellectual property portfolio through existing patent applications and operates commercial real estate [5]

Core Viewpoint - Avalon GloboCare Corp. has regained compliance with Nasdaq's minimum stockholders' equity requirement, allowing its common stock to continue being listed and traded on the Nasdaq Capital Market [1][2][3] Company Overview - Avalon GloboCare Corp. is a diversified company focused on developing precision diagnostic consumer products and advancing intellectual property in cellular therapy and generative AI publishing and software [4] - The company is currently marketing the KetoAir™ breathalyzer device, which is registered with the U.S. FDA as a Class I medical device, and plans to develop additional diagnostic uses for this technology [4] Financial Position - The company has made progress in strengthening its financial position, which is reflected in its regained compliance with Nasdaq's requirements [3] - The cancellation of the previously scheduled hearing before the Nasdaq Hearings Panel indicates a positive development for the company's stock listing status [2] Growth Initiatives - With full Nasdaq compliance restored, the company is positioned to execute growth initiatives, including launching marketing for its generative AI video platform and expanding its precision diagnostics and strategic assets [3]

Core Viewpoint - Avalon GloboCare Corp. has regained compliance with Nasdaq's minimum stockholders' equity requirement, allowing its common stock to continue being listed and traded on the Nasdaq Capital Market [1][2]. Financial Compliance - Nasdaq confirmed that Avalon is now in compliance with all applicable continued listing standards, leading to the cancellation of a previously scheduled hearing before the Nasdaq Hearings Panel [2]. - The company expressed satisfaction with its regained compliance, highlighting the progress made in strengthening its financial position and focusing on long-term shareholder value [3]. Growth Initiatives - With full Nasdaq compliance restored, Avalon is positioned to execute growth initiatives, including launching marketing for its generative AI video platform and expanding in precision diagnostics and strategic assets [3]. Company Overview - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and advancing intellectual property in cellular therapy and generative AI publishing and software through its subsidiary Avalon Quantum AI, LLC [4]. - The company is currently marketing the KetoAir™ breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device, and plans to develop additional diagnostic uses for this technology [4].

Core Viewpoint - Avalon GloboCare Corp. has acquired RPM Interactive, Inc., a generative AI publishing and software company, and is focusing on the development and commercialization of the Catch-Up platform, a SaaS solution for automated video generation [1][2]. Group 1: Acquisition and Leadership - Michael Mathews, CEO of RPM and a board member of Avalon, discussed the acquisition and its implications during an interview [1]. - The acquisition of RPM is part of Avalon's strategy to enhance its product offerings in the precision diagnostic consumer products sector [1]. Group 2: Catch-Up Platform Development - The Catch-Up platform is designed to automatically generate recap-style videos using generative AI applications and large language models [2]. - This platform will be marketed to content creators, media companies, and brands, allowing them to produce videos without manual editing or technical expertise [3]. Group 3: Marketing and Product Integration - Avalon plans to utilize the Catch-Up platform to support marketing initiatives for its KetoAir™ breathalyzer, which is FDA-registered and aimed at helping consumers manage their wellness [4]. - The integration of the Catch-Up platform is expected to enhance the volume of video content produced by content creators, thereby increasing engagement and visibility [3].